Business Context and Reporting Period
This Form 6-K filing by Zhengye Biotechnology Holding Ltd covers the month of June 2026. The report discloses the receipt of a Nasdaq Minimum Bid Price Deficiency Letter dated May 29, 2026, regarding the Company's Class A ordinary shares (trading symbol: ZYBT).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status regarding share price.
Material Changes and Regulatory Status
- Deficiency Trigger: The Company's Class A ordinary shares traded below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- Trading Status: Shares will continue to trade uninterrupted; immediate delisting is not in effect.
- Compliance Period: The Company has 180 calendar days (until November 25, 2026) to regain compliance.
- Compliance Criteria: The closing bid price must be at least $1.00 for a minimum of 10 consecutive business days during the compliance period.
Outlook, Risks, and Contingencies
Grace Period Option: If the Company fails to regain compliance by November 25, 2026, it may be eligible for an additional 180-day grace period. Qualification requires meeting the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market (excluding the bid price requirement).
Reverse Stock Split: To qualify for the grace period or cure the deficiency, the Company may effect a reverse stock split. If implemented, the split must be completed no later than 10 business days prior to November 25, 2026.
Risk: Failure to meet listing requirements could result in delisting from the Nasdaq Stock Market.
Investor Verification Checklist
- Verify the current closing bid price of ZYBT shares to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split before the November 25, 2026 deadline.
- Check the Company's market value of publicly held shares to determine eligibility for a potential grace period.
- Review subsequent press releases for confirmation of compliance or further deficiency notices.